HER2 Biomarkers
Menarini Group, Radius Health Advance Regulatory Plans for Elacestrant Breast Cancer Therapy
The drug improved progression-free survival over standard of care in ER-positive, HER2-negative advanced breast cancer patients with or without an ESR1 mutation.
Celcuity Studying Nerlynx Activity in HER2-Negative Breast Cancer With Hyperactive HER2 Signaling
The company will use its CELsignia test to identify metastatic breast cancer patients eligible to receive the pan-HER inhibitor with chemo within a Phase II trial.
Veru Launches Registrational Trial of Anti-Androgen Drug Enobosarm for Metastatic Breast Cancer
The Phase III ARTEST trial is enrolling pretreated patients with metastatic, HER2-negative, estrogen receptor-positive, and androgen receptor-positive cancers.
FDA Approves Eli Lilly's Verzenio as Adjuvant Therapy for High-Risk, Early Breast Cancer Patients
The decision follows results from the monarchE trial, in which the drug with endocrine therapy benefited early-stage breast cancer patients with a high Ki-67 score.
USC Opens Phase II Trial of Ambrx's ARX788 for HER2-Positive Breast Cancer
The trial will evaluate metastatic, pretreated breast cancer patients' overall response rates on the HER2-directed antibody-drug conjugate.